Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study
Status:
Recruiting
Trial end date:
2025-09-25
Target enrollment:
Participant gender:
Summary
HDAC inhibitor chidamide and PI3K inhibitor linperlisib has shown clinical activity as
mono-therapy in PTCL. The combination of duvelisib and romidepsin is highly active for
relapsed and refractory PTCLs. The aim of this study is to further explore the efficacy and
safety of HDAC inhibitor chidamide combined with PI3K inhibitor linperlisib in the treatment
of relapsed and refractory PTCLs.